Salute e Benessere

Crossject achieves key ZEPIZURE® manufacturing milestone

Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is part of the positive manufacturing data generated since 2021Manufacturing progress supports timelines toward granting of Emergency Use Authorization (EUA)Dijon, France, July 18, 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced...
Nasdaq GlobeNewswire
18/07/2024

Essity: Interim Report, Quarter 2, 2024

CEO'S COMMENTS CEO'S COMMENTS Essity is in better shape than ever, reporting strong second-quarter earnings with good underlying growth and its highest operating profit (EBITA) to date. All business areas achieved higher EBITA margins compared with the preceding year. We presented new ambitious financial targets during the quarter, and initiated a share buyback program. Higher volumesAll categories reported higher volumes, excluding the restructuring in Professional Hygiene, and in...
PR Newswire
18/07/2024

BioSenic releases new in-depth analysis of its positive phase 2 clinical data…

Press Release The upcoming Phase 3 trial with ATO is more robust following a new post-hoc analysis.Mont-Saint-Guibert, Belgium, July 18, 2024, 7.00 am CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases therapy, today announced the final results of a new, detailed post-hoc analysis of the Company's previous Phase 2 clinical trial of ATO for the first-line curative treatment of cGvHD. The...
Nasdaq GlobeNewswire
18/07/2024

Novartis continues to deliver strong sales growth and core margin expansion in…

Ad hoc announcement pursuant to Art. 53 LR Q2 net sales grew +11% (cc 1, +9% USD) with core operating income up +19% (cc, +17% USD)Sales growth driven by continued strong performance fromEntresto(+28% cc),Kesimpta(+65% cc),Cosentyx(+22% cc),Kisqali(+50% cc),Leqvio(+134% cc) andPluvicto(+44% cc)Core operating income margin 39.6%, +270 basis points (cc), mainly driven by higher net salesQ2 operating income grew +47% (cc, +43% USD) and net income…
Nasdaq GlobeNewswire
18/07/2024

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects…

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney DiseaseNew data confirm beneficial treatment effect of varoglutamstat on kidney functionTreatment effect 1in diabetes subgroup 2of >8mL/min/1.73m2/year in estimated glomerular filtration rate (eGFR); reinforces previously reported treatment effect of 3...
Nasdaq GlobeNewswire
18/07/2024

Junshi Biosciences Announces the Acceptance of the Supplemental New Drug…

®, product code: JS001) combined with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC). Liver cancer is a common malignant tumor of the digestive system worldwide, and the predominant pathological type is HCC (accounting for about 90% of global cases). According to the 2022 GLOBOCAN Report, there were 866,000 new cases and 759,000 deaths from liver cancer globally that year. China is particularly affected by liver cancer, with new liver...
Nasdaq GlobeNewswire
18/07/2024

China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature…

Portable Medical Devices Conduce to First Aid Efficiency the World Economic Forum projects that the climate crisis could lead to an alarming increase of 14.5 million deaths by 2050. The escalating extreme weather events has raised public awareness of the importance of first aid. Chinese companies have developed more convenient medical devices to assist in on-site rescue operations. For example, a portable emergency-specific Digital Radiography (DR) system weighs only 23 kilograms, features an…
PR Newswire
18/07/2024

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its…

NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia AALTUVIIIO provides high-sustained factor levels with once-weekly dosing in children under 12 with hemophilia A XTEND-Kids results show highly effective bleed protection in hemophilia A with no inhibitor development to factor VIII Paris, July 17, 2024– Full results from the XTEND-Kids phase 3 studypublishedinTheNew England...
Nasdaq GlobeNewswire
17/07/2024

Nipro Announces Major Expansion with New Medical Device Manufacturing Facility…

Nipro to Enhance Local Production and Job CreationFounded in Japan, Nipro stands as a Tier 1 manufacturer renowned for its high-quality medical devices and healthcare solutions. Tsuyoshi Yamazaki, Senior Managing Director of Global Business at Nipro, shared his excitement about the new facility. "We are thrilled to start manufacturing our cutting-edge medical devices in the U.S., which will support local healthcare professionals and patients with a stable supply chain and reduced…
PR Newswire
17/07/2024

Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31…

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website athttps://investor.jazzpharma.com/investors/events-presentations...
PR Newswire
17/07/2024

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary…

Participants completed primary vaccination series (3 doses) with VLA15 Primary vaccination series to be followed by a booster approximately one year after completion New York, NY and Saint-Herblain (France), July 17, 2024– Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the participants of the Phase 3 trial “Vaccine Against Lyme for Outdoor Recreationists” (VALOR) have completed the primary vaccination series (three doses) of Lyme...
Nasdaq GlobeNewswire
17/07/2024

Alkermes to Report Second Quarter Financial Results on July 24, 2024

About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes also has a corporate office and research…
PR Newswire
17/07/2024

New Nature publication confirms CARBIOS' leadership in enzymatic degradation of…

CARBIOS and Toulouse Biotechnology Institute (TBI) publish groundbreaking article that presents enzyme optimization work leading to an enzyme-embedded PLA able to disintegrate and biodegrade in home-compost conditions faster than certification timeframe requirementsThis new publication inNature, widely regarded as the most influential scientific journal, comes in addition to the2020 publication on enzymatic depolymerization of PET, confirming CARBIOS' leadership in enzymatic...
Nasdaq GlobeNewswire
17/07/2024

Roche's Vabysmo showed extended durability, continued efficacy and a consistent…

More than 90% of patients had absence of DME after four years in a pre-specified exploratory endpointPeople treated with Vabysmo sustained vision gains and anatomical improvements, with almost 80% receiving treatment at intervals of three or four months, in an exploratory analysis The study met all primary endpoints, showing safety data were consistent with Vabysmo's known safety profileThis is the largest long-term extension dataset in DME to-date, demonstrating consistent...
Nasdaq GlobeNewswire
17/07/2024

Surge in Prevalence of Venous Disorders Drives Venous Stents Market to Reach US$…

The venous stents market is experiencing significant growth, driven by a combination of increasing incidence of venous obstructive disorders and a surging global geriatric population. Venous stents, crucial for treating conditions such as deep vein thrombosis (DVT) and chronic venous insufficiency, are seeing heightened demand as these conditions become more prevalent. The venous stents market is experiencing significant growth, driven by a combination of increasing incidence of venous...
PR Newswire
17/07/2024

Digital Pathology Market worth $2.0 billion by 2029 driven by Technological…

Browse in-depth TOC on "Digital Pathology Market" Browse in-depth TOC on "Digital Pathology Market" 248 - Tables47 - Figures 325 - Pages DANAHER CORPORATION (US): Leader in Digital Pathology Solutions Danaher Corporation, through its subsidiary Leica Biosystems, has established itself as a strong player in the digital pathology market, offering a comprehensive portfolio from biopsy to diagnosis across radiology, pathology, surgery, and oncology. Strategic partnerships...
PR Newswire
17/07/2024

Bioanalytical Testing Services Market: Rising Demand for Precision Drives 15%…

WuXi AppTec's laboratory testing department has increased productivity by 400% since its early start in implementing bioanalytical automation. The bioanalytical testing services market includes CROs and other providers of bioanalytical testing services to the pharma and biotech industries. WuXi AppTec's laboratory testing department has increased productivity by 400% since its early start in implementing bioanalytical automation. The bioanalytical testing services market includes CROs and…
PR Newswire
17/07/2024

Cancer/Tumor Profiling Market to be Worth $24.70 Billion by 2031 - Exclusive…

Cancer/tumor profiling is widely conducted in clinical and research settings. The growth of this market is driven by factors such as the increasing prevalence of cancer, the rising pharmaceutical R&D expenditures, the growing number of targeted therapies and the discovery of new actionable biomarkers, increasing investments in cancer research, the declining costs of NGS-based profiling, and advancements in multi-omics tumor profiling. However, the high capital investments required for NGS…
PR Newswire
17/07/2024

AI-Based Medical Diagnostic Tools Market Set to Exceed USD 11.5 Billion by 2034…

In addition to enhancing the efficiency of existing algorithms, this involves investigating new artificial intelligence approaches such as deep learning, reinforcement learning, and federated learning for medical applications. In addition to enhancing the efficiency of existing algorithms, this involves investigating new artificial intelligence approaches such as deep learning, reinforcement learning, and federated learning for medical applications. AI-based diagnostic tools can empower...
PR Newswire
17/07/2024

Bon Secours Mercy Health and Philips sign multi-year strategic collaboration

Patient monitoring platform to deliver tools and time to help patients across 40+ care sitesAmsterdam, the Netherlands, and Cincinnati, Ohio – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology and Bon Secours Mercy Health (BSMH), one of the nation's largest Catholic health systems, today announced a multi-year strategic collaboration for patient monitoring. Putting BSMH clinicians in control, the collaboration will reduce the digital burden on staff and...
Nasdaq GlobeNewswire
17/07/2024

Hemostasis Products Market to Reach USD 4.5 Billion by 2034, Driven by a 5.7%…

With the growing number of accidental cases, the number of surgeries required is proliferating. Due to this rising number, the demand for hemostasis products is expected to increase, which will likely drive the global landscape. The rising number of chronic diseases is expected to fuel the demand for surgical interventions. With the growing number of accidental cases, the number of surgeries required is proliferating. Due to this rising number, the demand for hemostasis products is expected…
PR Newswire
17/07/2024

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024

Company Announcement Net sales of DARZALEX ®in the second quarter of 2024 totaled USD 2,878 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; July 17, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ®(daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEXFASPRO®...
Nasdaq GlobeNewswire
17/07/2024

Drugs of Abuse Testing Market Fueled by Rise in Drug Abuse Cases: 13.5% CAGR to…

Specific policies for drug abuse testing may differ throughout organizations and environments. For instance, the Department of Health and Human Services (DHHS) has mandatory occupational urine testing criteria that normally include testing for five substances of abuse: amphetamines, cannabis, cocaine, opiates, and PCP. However, other drugs might also be checked for depending on the particulars. Specific policies for drug abuse testing may differ throughout organizations and environments...
PR Newswire
17/07/2024

Grünenthal announces significant investments in its Latin America production…

"Our investment in Latin America is a strong demonstration of our commitment to long-term competitiveness in the region," says Victor Barbosa, Head of Global Operations and member of the Executive Board Team. "Future-proofing our manufacturing capabilities underscores our commitment to ensuring a safe, reliable, and efficient supply of medicine to patients globally. Grünenthal delivers high-quality medicine from Latin America to the world—a unique capability in the region."…
PR Newswire
17/07/2024
Altri  Comunicati